15517 Eczema Area and Severity Index 90 (EASI-90) responder rates with abrocitinib and relationship with quality of life (QoL) and itch in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 2020-12, Vol.83 (6), p.AB41-AB41
Main Authors: Yosipovitch, Gil, Bieber, Thomas, Gold, Linda Stein, Kwatra, Shawn, Tatulych, Svitlana, Nduaka, Chudy, Cameron, Michael C., Williams, David, Biswas, Pinaki, Valdez, Hernan
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2020.06.252